D. E. Shaw & Co., Inc. Tg Therapeutics, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $122 Billion
- Q4 2024
A detailed history of D. E. Shaw & Co., Inc. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 55,900 shares of TGTX stock, worth $1.68 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55,900
Previous 394,779
85.84%
Holding current value
$1.68 Million
Previous $9.23 Million
81.78%
% of portfolio
0.0%
Previous 0.01%
Shares
30 transactions
Others Institutions Holding TGTX
# of Institutions
372Shares Held
85.5MCall Options Held
3.78MPut Options Held
3M-
Vanguard Group Inc Valley Forge, PA15.6MShares$469 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$343 Million0.0% of portfolio
-
State Street Corp Boston, MA9.2MShares$277 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.19MShares$96.1 Million0.01% of portfolio
-
Pictet Asset Management Holding Sa Carouge, V82.79MShares$84.1 Million0.09% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $4.37B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...